NLRP3 and Alzheimer disease: Nicotinamide mononucleotide (NMN), an NAD+ precursor, represents a promising therapeutic strategy by enhancing mitochondrial function, reducing oxidative stress, and modulating NLRP3 inflammasome activation, with preclinical AD models showing improved cognitive function and reduced neuroinflammation [69].